Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 5 - Studien 41 bis 50 von insgesamt 75
- Rekrutierung läuftA PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB VERSUS SOTORASIB OR ADAGRASIB IN PATIENTS WITH PREVIOUSLY TREATED KRAS G12C-POSITIVE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
- Rekrutierung läuftA Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma
- Rekrutierung läuftInternational cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma
- Rekrutierung läuftTreatment Optimization for Children with De Novo and Relapsed Langerhans cell
Histiocytosis (LCH) as Part of the International Study LCH-IV - Rekrutierung läuft56021927PCR3020 (LIBERTAS) Eine offene, randomisierte, prospektive Phase-3-Studie zu Apalutamid mit fortgesetzter versus intermittierender Androgenentzugstherapie (ADT) nach PSA-Ansprechen bei Teilnehmern mit metastasiertem kastrationsempfindlichem Prostatakrebs (mCSPC)Indikationen
- Rekrutierung läuftA Phase 3, Randomized, International Multicenter Trial for Patients with Pediatric Low Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic TherapyMolekulare Marker
- Rekrutierung läuft
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (BRUIN CLL-322)
- Rekrutierung läuftA Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)Molekulare Marker
- Rekrutierung läuftA Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1)Molekulare Marker
- Rekrutierung läuftMAKEI V Multicentre prospective randomized study for extra-cranial germ cell tumours